Cargando…

Combination therapy is not associated with improved rates of clinical or endoscopic remission in patients with inflammatory bowel disease treated with ustekinumab or vedolizumab: a retrospective study

BACKGROUND: Management of inflammatory bowel disease (IBD) involves biological agents, often in combination with thiopurines or methotrexate. The aim of our study was to compare clinical and endoscopic outcomes in IBD patients treated with vedolizumab or ustekinumab, as monotherapy or in combination...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeffrey, Angus W., Picardo, Sherman, Menon, Shankar, So, Kenji, Venugopal, Kannan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Gastroenterology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10304522/
https://www.ncbi.nlm.nih.gov/pubmed/37396006
http://dx.doi.org/10.20524/aog.2023.0808
_version_ 1785065529842597888
author Jeffrey, Angus W.
Picardo, Sherman
Menon, Shankar
So, Kenji
Venugopal, Kannan
author_facet Jeffrey, Angus W.
Picardo, Sherman
Menon, Shankar
So, Kenji
Venugopal, Kannan
author_sort Jeffrey, Angus W.
collection PubMed
description BACKGROUND: Management of inflammatory bowel disease (IBD) involves biological agents, often in combination with thiopurines or methotrexate. The aim of our study was to compare clinical and endoscopic outcomes in IBD patients treated with vedolizumab or ustekinumab, as monotherapy or in combination with thiopurines or methotrexate. METHODS: We conducted a retrospective cohort study of all patients aged ≥18 years with a diagnosis of ulcerative colitis or Crohn’s disease, commenced on vedolizumab or ustekinumab between October 2015 and March 2022. Primary outcome was clinical remission or response calculated by partial Mayo score (remission: <3; response: improvement >1) for ulcerative colitis or Harvey-Bradshaw index (<5, >2 respectively) for Crohn’s disease over 1 year. Secondary endpoints were treatment failure, relapse, endoscopic remission at 1 year. Statistical analysis was done using 2-sample Student’s t and chi-square tests. RESULTS: A total of 159 IBD patients were included in the study, 85 (53%) on vedolizumab and 74 (47%) on ustekinumab. For those on vedolizumab, 61 (72%) patients had ulcerative colitis, and 24 (28%) has Crohn’s disease. All patients on ustekinumab had Crohn’s disease. Mean disease duration in was 9.4 and 13.5 years respectively. There was no difference in clinical response or remission for vedolizumab or ustekinumab monotherapy compared to combination therapy at 1 year. There was also no difference in treatment failure, relapse or endoscopic remission. CONCLUSION: Combining vedolizumab or ustekinumab with an immunomodulator is not superior to monotherapy in terms of clinical response or endoscopic remission up to 1 year in IBD.
format Online
Article
Text
id pubmed-10304522
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Hellenic Society of Gastroenterology
record_format MEDLINE/PubMed
spelling pubmed-103045222023-07-01 Combination therapy is not associated with improved rates of clinical or endoscopic remission in patients with inflammatory bowel disease treated with ustekinumab or vedolizumab: a retrospective study Jeffrey, Angus W. Picardo, Sherman Menon, Shankar So, Kenji Venugopal, Kannan Ann Gastroenterol Original Article BACKGROUND: Management of inflammatory bowel disease (IBD) involves biological agents, often in combination with thiopurines or methotrexate. The aim of our study was to compare clinical and endoscopic outcomes in IBD patients treated with vedolizumab or ustekinumab, as monotherapy or in combination with thiopurines or methotrexate. METHODS: We conducted a retrospective cohort study of all patients aged ≥18 years with a diagnosis of ulcerative colitis or Crohn’s disease, commenced on vedolizumab or ustekinumab between October 2015 and March 2022. Primary outcome was clinical remission or response calculated by partial Mayo score (remission: <3; response: improvement >1) for ulcerative colitis or Harvey-Bradshaw index (<5, >2 respectively) for Crohn’s disease over 1 year. Secondary endpoints were treatment failure, relapse, endoscopic remission at 1 year. Statistical analysis was done using 2-sample Student’s t and chi-square tests. RESULTS: A total of 159 IBD patients were included in the study, 85 (53%) on vedolizumab and 74 (47%) on ustekinumab. For those on vedolizumab, 61 (72%) patients had ulcerative colitis, and 24 (28%) has Crohn’s disease. All patients on ustekinumab had Crohn’s disease. Mean disease duration in was 9.4 and 13.5 years respectively. There was no difference in clinical response or remission for vedolizumab or ustekinumab monotherapy compared to combination therapy at 1 year. There was also no difference in treatment failure, relapse or endoscopic remission. CONCLUSION: Combining vedolizumab or ustekinumab with an immunomodulator is not superior to monotherapy in terms of clinical response or endoscopic remission up to 1 year in IBD. Hellenic Society of Gastroenterology 2023 2023-05-29 /pmc/articles/PMC10304522/ /pubmed/37396006 http://dx.doi.org/10.20524/aog.2023.0808 Text en Copyright: © Hellenic Society of Gastroenterology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Jeffrey, Angus W.
Picardo, Sherman
Menon, Shankar
So, Kenji
Venugopal, Kannan
Combination therapy is not associated with improved rates of clinical or endoscopic remission in patients with inflammatory bowel disease treated with ustekinumab or vedolizumab: a retrospective study
title Combination therapy is not associated with improved rates of clinical or endoscopic remission in patients with inflammatory bowel disease treated with ustekinumab or vedolizumab: a retrospective study
title_full Combination therapy is not associated with improved rates of clinical or endoscopic remission in patients with inflammatory bowel disease treated with ustekinumab or vedolizumab: a retrospective study
title_fullStr Combination therapy is not associated with improved rates of clinical or endoscopic remission in patients with inflammatory bowel disease treated with ustekinumab or vedolizumab: a retrospective study
title_full_unstemmed Combination therapy is not associated with improved rates of clinical or endoscopic remission in patients with inflammatory bowel disease treated with ustekinumab or vedolizumab: a retrospective study
title_short Combination therapy is not associated with improved rates of clinical or endoscopic remission in patients with inflammatory bowel disease treated with ustekinumab or vedolizumab: a retrospective study
title_sort combination therapy is not associated with improved rates of clinical or endoscopic remission in patients with inflammatory bowel disease treated with ustekinumab or vedolizumab: a retrospective study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10304522/
https://www.ncbi.nlm.nih.gov/pubmed/37396006
http://dx.doi.org/10.20524/aog.2023.0808
work_keys_str_mv AT jeffreyangusw combinationtherapyisnotassociatedwithimprovedratesofclinicalorendoscopicremissioninpatientswithinflammatoryboweldiseasetreatedwithustekinumaborvedolizumabaretrospectivestudy
AT picardosherman combinationtherapyisnotassociatedwithimprovedratesofclinicalorendoscopicremissioninpatientswithinflammatoryboweldiseasetreatedwithustekinumaborvedolizumabaretrospectivestudy
AT menonshankar combinationtherapyisnotassociatedwithimprovedratesofclinicalorendoscopicremissioninpatientswithinflammatoryboweldiseasetreatedwithustekinumaborvedolizumabaretrospectivestudy
AT sokenji combinationtherapyisnotassociatedwithimprovedratesofclinicalorendoscopicremissioninpatientswithinflammatoryboweldiseasetreatedwithustekinumaborvedolizumabaretrospectivestudy
AT venugopalkannan combinationtherapyisnotassociatedwithimprovedratesofclinicalorendoscopicremissioninpatientswithinflammatoryboweldiseasetreatedwithustekinumaborvedolizumabaretrospectivestudy